Prostamax Peptide: Mechanism of Action
Research suggests that an artificial Khavinson peptide, Prostamax, may primarily act to change DNA expression patterns in many organs and enhance lymphocyte function. By encouraging heterochromatin decondensing in a wide range of cell types, Prostamax has earned a place among the broader-spectrum anti-aging Khavinson peptides. The potential of Prostamax in alleviating chronic prostatitis has been speculated in rat studies. Although there have not been trials of adequate duration to prove it, there is conjecture that long-term exposure may have impacts in the onset of cancer cell proliferation and development.
Prostamax Peptide and the Prostate
According to studies conducted on rats, Prostamax seems to help alleviate some of the symptoms of prostatitis. After just 15 days of presentation with Prostamax, rats have been hypothesized to exhibit less hyperemia (blood vessel congestion), decreased immune cell infiltration, and reduced prostate gland edema. Curiously, the rats appeared to have less scarring in the prostate, suggesting that the inflammation reduction was halting or at least slowing down pathological remodeling. Results indicate that Prostamax would likely reduce the risk of cancer by lowering chronic inflammation that leads to pathological hypertrophy and hyperplasia. However, the trial did not last long enough or use enough rats to determine the impact on cancer risk.
Even though bacteria don't cause it, CAP has unique challenges, making it the most frequent prostatitis. Antibiotics are considered to work well against bacterial illnesses. In contrast, antibiotics for CAP is considered to be subpar at best and often may have no effect.
Prostamax Peptide and Immunity
There is substantial data suggesting that the bioregulator may affect cells outside the prostate, notwithstanding Prostamax's tissue-specificity. The ribosomes and tightly packed chromatin of lymphocytes are the ones most affected. Like Epithalon and Vilon, Prostamax has been theorized to enhance ribosome expression in these cells, allowing for more efficient translation of messenger RNA (mRNA) into proteins. In order to facilitate transcription into messenger RNA, it has also been hypothesized to loosen tightly packed chromatin. Investigations purport that Prostamax may improve lymphocyte function by facilitating a functional shift in gene expression at all levels.
Furthermore, Prostamax's effect on the immune system is more than hypothetical. Scientific studies have suggested that this peptide may alleviate edema, hyperemia, and lymphocyte infiltration, all of which are symptoms of chronic inflammation in the prostate. Third, the peptide's function in regulating the development and differentiation of prostate cells and its effect on lymphocytes, which regulate the immunological response, may contribute to this effect.
Prostamax Peptide and Cell Aging
Findings imply that Prostamax may affect many cell types, including lymphocytes and prostate cells, among many others. Decondensing heterochromatin is one way that Prostamax has been speculated to change DNA structure, according to studies conducted on cell cultures collected from aged animal research models. As a result, tight DNA packing enables increased expression of inactivated DNA.
Since DNA condensation is a natural but unpleasant byproduct of cell senescence, this may be particularly noteworthy from a cell aging perspective. DNA condensation is an essential aspect of cell aging, which may play a key role in senescence and apoptosis. Studies suggest Prostamax may give cells a younger genetic profile by unpacking DNA. Protein expression and cellular function appear enhanced, while cell proliferation and apoptosis (programmed cell death) seem reduced.
Curiously, long-lived rodents such as the African mole rat naturally contain Prostamax and comparable epigenetically active peptides. This suggests that the reported epigenetic effects of Prostamax peptides may be associated with cell aging and longevity.
Prostamax Peptide: Summary
Synthesized from the Khavinson peptide, Prostamax has been hypothesized to impact DNA condensation significantly in many cell types. Research has indicated that it may improve the function of many other cells (such as lymphocytes) by modifying epigenetic restrictions on DNA.
References
[i] A. N. Zakutskiĭ, N. I. Chalisova, G. A. Ryzhak, A. I. Aniskina, S. V. Filippov, and P. N. Zeziulin, “[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats],” Adv. Gerontol. Uspekhi Gerontol., vol. 19, pp. 93–96, 200
[ii] “Treating chronic prostatitis,” Harvard Health, Dec. 21, 2017. https://www.health.harvard.edu/mens-health/treating-chronic-prostatitis (accessed Jan. 12, 2024).
[iii] T. G. Borovskaya et al., “Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications,” Mod. Res. Inflamm., vol. 2013, Jul. 2013, doi: 10.4236/mri.2013.23007.
[iv] V. K. Khavinson, T. A. Lezhava, and V. V. Malinin, “Effects of short peptides on lymphocyte chromatin in senile subjects,” Bull. Exp. Biol. Med., vol. 137, no. 1, pp. 78–81, Jan. 2004, doi: 10.1023/b:bebm.0000024393.40560.05.
[v] T. Meskhi et al., “[The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ],” Biofizika, vol. 49, no. 6, pp. 1091–1093, Dec. 2004.
[vi] T. A. Dzhokhadze, T. Z. Buadze, M. N. Gaĭozishvili, N. A. Baratashvili, and T. A. Lezhava, “[Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)],” Georgian Med. News, no. 212, pp. 76–82, Nov. 2012.
[vii] V. K. Khavinson, D. Y. Kormilets, and A. T. Mar’yanovich, “Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan,” Bull. Exp. Biol. Med., vol. 163, no. 5, pp. 671–676, Sep. 2017, doi: 10.1007/s10517-017-3876-x.
Daily Voice is not a scientific journal and has not verified any scientific claims or citations in this article.
